IMPORTANT NOTE: This guideline applies only to the reporting of SAEs during clinical trials. An update of the guideline for this purpose is being developed. The reporting of post-marketing ADRs is described in guideline 2.33 REPORTING OF POST-MARKETING ADVERSE DRUG REACTIONS TO HUMAN MEDICINAL PRODUCTS IN SOUTH AFRICA